{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:40:49Z","timestamp":1790138449552,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There are limited data exploring antiretroviral therapy (ART) changes and time to change among South Africa young people living with HIV\/AIDS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>We describe the time to first drug switch, which includes ART regimen change (three drug switch) and substitutions (single drug switch). We describe common reasons for ART switch among young people aged 10 to 24\u00a0years in South Africa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study at a primary health care clinic in Cape Town, South Africa, providing ART to HIV-infected adolescents and adults since 2002. Those aged 10 to 24\u00a0years at ART initiation, who accessed care clinic between September 2002 and April 2019. Data was retrieved from electronic information systems: ART regimens, ART changes, dates for initiation or stop of each drug\/regimen, laboratory results (viral loads, haemoglobin, liver enzyme results, and creatinine to support the reason for ART switch. From written records, we abstracted reason for single drug switch or regimen change, as well as socio demographic and clinical data. We fitted cox regression models to determine factors associated with ART switch (Having a change in one or more drugs in ART combination) and the rate of occurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 2601 adolescents included, 605 (24.9%) adolescents switched ART over 5090.5 person years at risk (PYAR), a rate of 11.9 \/100PYAR. Median follow-up time was 4.4 (\u00b1\u20093.2) years. At multivariable analysis, the older age group was protective of the risk of ART switch: adjusted Hazard Ratio [aHR] 0.78, 95% CI 0.62\u20130.98, transfer status [transferred out 1.42 [1.11\u20131.82]. The hazard of ART switch increased with more severe HIV-disease at ART start, as observed by increasing WHO clinical stage or reduced CD4 count at baseline. The primary reasons for ART switch were side effects (20.0%), virological failure (17.9%) and formulation switch (27.8%). Others reasons included pregnancy, Hepatitis B, tuberculosis and psychosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ART switches are frequent and occur at a consistent rate across 7.5\u00a0years from initiation. The main reasons for ART switch were virological failure and drug side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-022-00453-4","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T10:16:59Z","timestamp":1656411419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa (2002\u20132019)"],"prefix":"10.1186","volume":"19","author":[{"given":"Anita","family":"Kabarambi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Balinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Abaasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolphina","family":"Cogill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"453_CR1","unstructured":"UNICEF. HIV and AIDS in adolescents. 2020 (Accessed 15 March 2021)."},{"key":"453_CR2","unstructured":"UNAIDs. Ending the AIDS epidemic for adolescents, with adolescent: a practical guide to meaningfully engage adolescents in the AIDS response. 2016. https:\/\/www.unfpa.org\/sites\/default\/files\/pub-pdf\/210079_UNAIDS_ENDING_THE_AIDS_FINAL_SO.pdf. (Accessed 09 June 2022)"},{"key":"453_CR3","unstructured":"UNAIDs. UNAIDs data 2019. 2019. https:\/\/www.unaids.org\/en\/resources\/documents\/2019\/2019-UNAIDS-data."},{"key":"453_CR4","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"WH Organization","year":"2016","unstructured":"Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Genva: World Health Organization; 2016."},{"issue":"10","key":"453_CR5","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","volume":"4","author":"S Kanters","year":"2017","unstructured":"Kanters S, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis. The lancet HIV. 2017;4(10):e433\u201341.","journal-title":"The lancet HIV"},{"issue":"12","key":"453_CR6","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/cid\/cix1108","volume":"66","author":"AJ Stockdale","year":"2018","unstructured":"Stockdale AJ, et al. Effectiveness of protease inhibitor\/nucleos (t) ide reverse transcriptase inhibitor\u2013based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(12):1846\u201357.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"453_CR7","doi-asserted-by":"publisher","first-page":"e63596","DOI":"10.1371\/journal.pone.0063596","volume":"8","author":"C Njuguna","year":"2013","unstructured":"Njuguna C, et al. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS ONE. 2013;8(5):e63596.","journal-title":"PLoS ONE"},{"key":"453_CR8","unstructured":"Africa, D.o.H.R.o.S. Clinical guidelines for the management of HIV & AIDS in adults and adolescents 2010. https:\/\/sahivsoc.org\/Files\/Clinical_Guidelines_for_the_Management_of_HIV_AIDS_in_Adults_Adolescents_2010.pdf. (Accessed 22 Jan 2021)"},{"key":"453_CR9","first-page":"1","volume":"25","author":"LR Danil","year":"2020","unstructured":"Danil LR. Queerphobic immunopolitics in the case of HIV\/AIDS: political economy, the dark legacy of british colonialism, and queerphobia in Sub-Saharan Africa. Sexual Culture. 2020;25:1\u201319.","journal-title":"Sexual Culture."},{"issue":"4","key":"453_CR10","doi-asserted-by":"publisher","first-page":"e8155","DOI":"10.2196\/mhealth.8155","volume":"6","author":"L Whiteley","year":"2018","unstructured":"Whiteley L, et al. A mobile gaming intervention to increase adherence to antiretroviral treatment for youth living with HIV: development guided by the information, motivation, and behavioral skills model. JMIR Mhealth Uhealth. 2018;6(4):e8155.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"3","key":"453_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1468-1293.2007.00451.x","volume":"8","author":"E Hart","year":"2007","unstructured":"Hart E, et al. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-na\u00efve patients. HIV Med. 2007;8(3):186\u201391.","journal-title":"HIV Med"},{"issue":"2","key":"453_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1468-1293.2009.00750.x","volume":"11","author":"P Cicconi","year":"2010","unstructured":"Cicconi P, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104\u201313.","journal-title":"HIV Med"},{"issue":"14","key":"453_CR13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/QAD.0b013e32832e05b2","volume":"23","author":"O Keiser","year":"2009","unstructured":"Keiser O, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867.","journal-title":"AIDS"},{"key":"453_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.puhe.2017.12.010","volume":"157","author":"N Ammon","year":"2018","unstructured":"Ammon N, Mason S, Corkery J. Factors impacting antiretroviral therapy adherence among human immunodeficiency virus\u2013positive adolescents in Sub-Saharan Africa: a systematic review. Public Health. 2018;157:20\u201331.","journal-title":"Public Health"},{"issue":"12","key":"453_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1089\/apc.2008.0048","volume":"22","author":"C Merzel","year":"2008","unstructured":"Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDS. 2008;22(12):977\u201387.","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"453_CR16","doi-asserted-by":"publisher","first-page":"21437","DOI":"10.7448\/IAS.20.1.21437","volume":"20","author":"MH Kim","year":"2017","unstructured":"Kim MH, et al. High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: barriers and associated factors. J Int AIDS Soc. 2017;20(1):21437.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"453_CR17","first-page":"1","volume":"29","author":"P Kazooba","year":"2018","unstructured":"Kazooba P, et al. Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy\u2013evidence from a prospective cohort study in rural South-Western Uganda, 2004\u20132011. Pan African Med J. 2018;29(1):1\u201316.","journal-title":"Pan African Med J"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00453-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-022-00453-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00453-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T10:31:33Z","timestamp":1656412293000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-022-00453-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1186\/s12981-022-00453-4","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We have ongoing ethical approval from the University of Cape Town Research Ethics Committee to collect routine clinical data from those in care at the HCTC and to use anonymized data from the HCTC for research purposes and publication. This approval was first granted in 2002, and is renewed every year. No written informed consent was provided by the patients. All identifying data is removed prior to data leaving the site or being sent to collaborators. Patient\u2019s data were identified by coded numbers only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}